AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is currently conducting a clinical study titled A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics. The study aims to assess the impact of benralizumab on lung structure and function in patients with severe eosinophilic asthma who continue to experience symptoms despite standard treatments.
The intervention being tested is benralizumab, a biological treatment administered subcutaneously. It is designed to improve lung function and reduce structural changes in patients with severe eosinophilic asthma.
This interventional study follows a randomized, parallel-group design with triple masking (participant, care provider, investigator) to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide new insights into managing severe asthma.
The study began on October 17, 2019, and is currently recruiting participants. The most recent update was submitted on July 14, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature.
The outcome of this study could significantly influence AstraZeneca’s stock performance by potentially expanding its market share in asthma treatments. Positive results may enhance investor confidence, especially in the competitive landscape of respiratory treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.